2022
Current Landscape and Future Directions of Coronary Revascularization in Patients With Heart Failure
Ahmad Y, Lansky AJ, Velazquez EJ. Current Landscape and Future Directions of Coronary Revascularization in Patients With Heart Failure. JAMA Cardiology 2022, 7: 577-578. PMID: 35476046, DOI: 10.1001/jamacardio.2022.0659.Peer-Reviewed Original Research
2012
The Generations of Drug-Eluting Stents and Outcomes in Women
Ng VG, Lansky AJ. The Generations of Drug-Eluting Stents and Outcomes in Women. Interventional Cardiology Clinics 2012, 1: 183-195. PMID: 28582092, DOI: 10.1016/j.iccl.2012.01.002.Peer-Reviewed Original ResearchDrug-eluting stentsPercutaneous coronary artery revascularizationObstructive coronary artery diseaseCoronary artery revascularizationMinority of patientsCoronary artery diseaseCause of deathDrug-eluting stent technologyDrug eluting stentsArtery revascularizationArtery diseaseClinical trialsCardiovascular diseaseAntiproliferative drugsStentsStent technologyWomenStent platformsDiseaseOutcomesRevascularizationPatientsMainstayPrevalenceTrials
2010
The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention.
Saltzman AJ, Mehran R, Hooper WC, Moses JW, Weisz G, Collins MB, Lansky AJ, Kreps EM, Leon MB, Stone GW, Dangas G. The relative effects of abciximab and tirofiban on platelet inhibition and C-reactive protein during coronary intervention. Journal Of Invasive Cardiology 2010, 22: 2-6. PMID: 20048389.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngina, UnstableAngioplasty, Balloon, CoronaryAntibodies, MonoclonalBlood PlateletsC-Reactive ProteinDose-Response Relationship, DrugDouble-Blind MethodDrug Therapy, CombinationFemaleHeparinHumansImmunoglobulin Fab FragmentsMaleMiddle AgedPilot ProjectsPlatelet AggregationPlatelet Aggregation InhibitorsStentsTime FactorsTirofibanTyrosineConceptsPercutaneous coronary interventionC-reactive proteinTarget vessel revascularizationPlatelet inhibitionCoronary interventionLevels of CRPInflammatory markers C-reactive proteinPlatelet aggregationC-reactive protein levelsDouble-blind study designEfficacy of tirofibanLower platelet inhibitionCoronary artery bypassCoronary artery revascularizationArtery revascularizationDiabetic subsetEligible patientsNonfatal MIArtery bypassHs-CRPVessel revascularizationSpearman correlation coefficient modelClinical endpointsFirst time pointTirofiban
2006
Serial Angiographic Follow-Up of Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Revascularization
Price MJ, Cristea E, Sawhney N, Kao JA, Moses JW, Leon MB, Costa RA, Lansky AJ, Teirstein PS. Serial Angiographic Follow-Up of Sirolimus-Eluting Stents for Unprotected Left Main Coronary Artery Revascularization. Journal Of The American College Of Cardiology 2006, 47: 871-877. PMID: 16487858, DOI: 10.1016/j.jacc.2005.12.015.Peer-Reviewed Original ResearchConceptsLate lossParent vesselUnprotected left main coronary artery stenosisLeft main coronary artery stenosisFinal minimal luminal diameterMain coronary artery revascularizationMain coronary artery stenosisSirolimus-eluting stent implantationEfficacy of SESCoronary artery revascularizationAngiographic Follow-upSirolimus-Eluting StentsCoronary artery stenosisMinimal luminal diameterArtery revascularizationCircumflex ostiumLesion restenosisLesion revascularizationLMCA diseaseLMCA interventionLMCA lesionsSES implantationAngiographic outcomesIndependent predictorsArtery stenosis